Recipharm, Tillotts Collaborate
News Sep 02, 2016
Recipharm has announced that it has entered into a long term supply agreement with Tillotts Pharma AG. The agreement comprises technology transfer and commercial manufacturing of the products Entocort and Asacol. The partnership will also involve the commercial scale development of Tillotts’ ongoing development programme for TP05. All products are part of Tillotts’ dedication to innovative pharmaceutical products in the field of gastroenterology.
Recipharm will provide advanced pellet coating technology for controlled release from its facility in
Pessac, France, tablet and capsule manufacturing including final packaging from its facility in
Fontaine, France, and bottle filling from its site in Lisbon, Portugal. The total shared investment
across the Recipharm network to enable this business amounts to €3.5 million. This includes
investments to create new capacity as well as product specific investments.
The collaboration between Recipharm and Tillotts Pharma AG marks an important step in
Recipharm’s full service offering strategy, allowing customers to fulfil their needs for different
technologies while working with Recipharm as one full service partner. This approach allows the
CDMO to simplify both the technology transfer and scale-up of projects, as well as ongoing
Kjell Johansson, President Manufacturing Services Europe at Recipharm, said: “We are really pleased that Tillotts Pharma AG has chosen Recipharm for these exciting products and projects. Our technical solutions offer a high level of customisation and we look forward to working with Tillotts to ensure their continued development and success within the gastroenterology area.”
Mattias Norrman, COO of Tillotts Pharma AG, said: “We have undertaken a thorough evaluation
process to ensure we partner with a CDMO that can meet the needs we have for project
management during technology transfer and scale-up, as well as fulfilling our requirements as a
reliable commercial supplier. We believe Recipharm is the ideal CDMO partner for this task and look forward to establishing a long term relationship.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.